Mouse 4-1BB Ligand/TNFSF9 Antibody Summary
Arg104-Glu309
Accession # P41274
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of 4-1BB Ligand/TNFSF9 by Western Blot Delta-24-ACT can be expressed in glioma cells and induces T cell activation. (A) 4-1BBL protein expression in CT-2A, GL261, GL261-5 and U87-MG cells infected with Delta-24-ACT and Delta-24-RGD at the indicated MOIs analyzed by flow cytometry (one-way ANOVA). (B) 4-1BBL protein expression in GL261-5 and CT-2A cells infected with Delta-24-ACT at the indicated MOIs analyzed by western blot analysis. A representative image is shown. (C) In vivo evaluation of 4-1BBL mRNA expression. The mRNA expression of 4-1BBL in mice bearing CT-2A tumors 3 days after treatment with Delta-24-ACT was analyzed by real-time PCR. The contralateral hemisphere was used as the negative control (Student’s t-test). (D) In vivo assessment of 4-1BBL mRNA expression in mice bearing CT-2A and U87-MG subcutaneously and treated with either Delta-24-RGD or Delta-24-ACT for 48 hours. Mice treated with PBS were used as controls. (E) IFN-gamma production by lymphocytes after Delta-24-ACT infection. CD8+ T cells from PMEL mice were cocultured with CT-2A cells infected with Delta-24-RGD or Delta-4-ACT at an MOI of 100. The secretion of IFN-gamma in the collected supernatants was quantified by ELISA. MOI, multiplicities of infection. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34281988), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: 4-1BB Ligand/TNFSF9
4-1BB ligand (4-1BBL) is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF9. Mouse 4-1BBL cDNA encodes a 309 amino acid residues (aa) protein with an 82 aa N-terminal cytoplasmic domain, a 21 aa transmembrane domain and a 206 aa C-terminal extracellular domain. The extracellular domain of 4-1BBL has a tertiary structure similar to that of other TNFSF members, but shares only low aa sequence homology (14‑16%). Murine 4-1BBL shares 36% aa sequence identity with its human counterpart (1, 2). 4-1BBL is predominantly expressed on activated antigen presenting cells (APCs) such as B cells, macrophages and dendritic cells (DCs). It is also expressed on most T and B lymphoma cell lines (3). A soluble 4-1BBL is released from the cell surface following cellular activation via proteolytic cleavage by one or more sheddases (4). By analogy to other TNFSF ligands, both the soluble and transmembrane 4-1BBL are expected to exist as non-covalent homotrimers. 4-1BBL binds 4-1BB, a TNF receptor superfamily member, TNFRSF9, which is also known as CD137 and ILA (induced by lymphocyte activation). 4-1BB is expressed on activated CD4+ and CD8+ T cells, thymocytes, and NK cells. It is also expressed on monocytes, neutrophils, DCs and eosinophils. In response to 4-1BBL binding, 4-1BB transduces a T cell costimulatory signal in both CD4+ and CD8+ T cells to promote survival and enhance proliferation, cytokine production and effector function. In dendritic cells, 4-1BB is a DC-activating molecule that enhances cytokine production and up‑regulates expression of B7-1 and B7-2 costimulatory molecules (3).
- Goodwin, R.G. et al. (1993) Eur. J. Immunol. 23:2631.
- Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
- Kwon, B., H.W. Lee and B.S Kwon (2002) TRENDS in Immunology 23:378.
- Salih, H.R. et al. (2001) J. Immunol. 167:4059.
Product Datasheets
Citations for Mouse 4-1BB Ligand/TNFSF9 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
8
Citations: Showing 1 - 8
Filter your results:
Filter by:
-
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Authors: Puigdelloses M, Garcia-Moure M, Labiano S Et Al.
Journal for immunotherapy of cancer
-
Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
Authors: V Laspidea, M Puigdellos, S Labiano, L Marrodán, M Garcia-Mou, M Zalacain, M Gonzalez-H, N Martínez-V, I Ausejo-Mau, D de la Nava, G Herrador-C, J Marco-Sanz, E Guruceaga, CE de Andrea, M Villalba, O Becher, M Squatrito, V Matía, J Gállego Pé, A Patiño-Gar, S Gupta, C Gomez-Manz, J Fueyo, MM Alonso
JCI Insight, 2022-04-08;7(7):.
Species: Mouse
Sample Types: Cell Lysates
Applications: Western Blot -
4-1BB ligand signaling to T cells limits T cell activation.
Authors: Eun S, Lee S, Xu Y, Croft M
J Immunol, 2014-11-17;194(1):134-41.
Species: Mouse
Sample Types: Whole Cells
Applications: ICC -
HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
Authors: Kanagavelu, Saravana, Termini, James M, Gupta, Sachin, Raffa, Francesc, Fuller, Katherin, Rivas, Yaelis, Philip, Sakhi, Kornbluth, Richard, Stone, Geoffrey
PLoS ONE, 2014-02-28;9(2):e90100.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.
Authors: Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee MG, Lee M, Kim H, Yun CO
Mol. Ther., 2009-09-08;18(2):264-74.
Species: Mouse
Sample Types: Cell Lysates
Applications: Western Blot -
Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages.
Authors: Kang YJ, Kim SO, Shimada S, Otsuka M, Seit-Nebi A, Kwon BS, Watts TH, Han J
Nat. Immunol., 2007-05-13;8(6):601-9.
Species: Mouse
Sample Types: Cell Lysates, In Vivo, Whole Cells
Applications: ICC, Neutralization, Western Blot -
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Authors: Suzanne Thomas, Linta Kuncheria, Victoria Roulstone, Joan N. Kyula, David Mansfield, Praveen K. Bommareddy et al.
Journal for ImmunoTherapy of Cancer
-
The TNF Family Member 4-1BBL Sustains Inflammation by Interacting with TLR Signaling Components During Late-Phase Activation
Authors: Jianhui Ma, Bo-Ram Bang, Jiawei Lu, So-Young Eun, Motoyuki Otsuka, Michael Croft et al.
Science Signaling
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Mouse 4-1BB Ligand/TNFSF9 Antibody
There are currently no reviews for this product. Be the first to review Mouse 4-1BB Ligand/TNFSF9 Antibody and earn rewards!
Have you used Mouse 4-1BB Ligand/TNFSF9 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
